INNOVENT BIO (01801.HK): Sintilimab Gets First CHMP Positive Opinion for First-Line NSCLC
NewTimeSpace News: On 16 November 2026, Innovent Biologics, Inc. (stock code: 1801) published a voluntary announcement that sintilimab, marketed in Europe as Zybrivo®, has received a first positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, which recommends a marketing authorisation for the drug combined with chemotherapy in adults with advanced non-squamous non-small cell lung cancer.
Sintilimab is a fully human immunoglobulin G4 monoclonal antibody that binds to programmed cell death protein 1. The recommended indication is Zybrivo with pemetrexed and platinum-based chemotherapy for first-line treatment of adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic tumour aberrations, whose disease is locally advanced and not amenable to curative surgery or chemoradiation, or metastatic.
The opinion is based on the Phase III ORIENT-11 study (NCT03607539), a randomised, multicentre, double-blind, placebo-controlled trial that enrolled 397 adults with locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer, randomised 2:1 to sintilimab or placebo, both with pemetrexed and platinum chemotherapy. Compared with placebo plus chemotherapy, sintilimab plus chemotherapy reduced the risk of disease progression or death by 52%, with median progression-free survival of 8.9 months versus 5.0 months, and reduced the risk of death by 35%, with median overall survival of 24.2 months versus 16.8 months. The safety profile was consistent with that known for PD-1 inhibitors and the chemotherapy used, with no new safety signals.
After the positive opinion, the European Commission is expected to decide on the marketing authorisation in the coming months. If approved, the authorisation would apply in all 27 EU member states as well as Iceland, Norway and Liechtenstein.
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output
- OSMUNDA: Closes RMB 100 Million Series D Led Exclusively by Lishui Green Valley Talent Osmunda New Fund
- EVEREST MED (01952.HK): Two Products Enter 2026 National Reimbursement List